Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple primary melanoma.

H S Moseley, A E Giuliano, F K Storm

    Cancer
    |March 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    FOXC1: an emerging marker and therapeutic target for cancer.

    Oncogene·2017
    Same author

    FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.

    Oncogene·2016
    Same author

    Long-term clinical impact of sentinel lymph node biopsy in breast cancer and cutaneous melanoma.

    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2014
    Same author

    Assessment of DNA methylation status in early stages of breast cancer development.

    British journal of cancer·2013
    Same author

    FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling.

    Oncogene·2012
    Same author

    Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis.

    Breast (Edinburgh, Scotland)·2009

    Patients with multiple primary melanomas often have better survival rates than those with a single melanoma. Prognosis depends more on the most advanced stage and lymph node involvement than the number of melanomas.

    Area of Science:

    • Dermatology
    • Oncology
    • Immunology

    Background:

    • Multiple primary melanomas occur in 5.3% of patients.
    • Synchronous primaries are diagnosed in 32% of patients with multiple melanomas.
    • Many multiple primaries are diagnosed within the first year of the initial diagnosis.

    Purpose of the Study:

    • To analyze the characteristics and outcomes of patients with multiple primary melanomas.
    • To investigate the relationship between melanoma multiplicity, microstaging, and patient prognosis.
    • To evaluate the efficacy of immunotherapy in preventing new melanoma development.

    Main Methods:

    • Retrospective analysis of 712 melanoma patients, identifying 38 with multiple primaries.
    • Microstaging (Breslow depth, Clark level) and lymph node status assessment.

    Related Experiment Videos

  • Cutaneous hypersensitivity testing with 2,4-dinitrochlorobenzene (DNCB).
  • Evaluation of adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy outcomes.

    • Main Results:

    • 83% of non-synchronous primaries were less advanced than the original.
    • No significant difference in DNCB reactions between multiple primary and single melanoma patients.
    • BCG immunotherapy did not prevent new melanoma development in 40% of patients.
    • Improved survival in Stage I and II multiple primary melanomas compared to single primary melanomas.

    Conclusions:

    • Prognosis in multiple primary melanomas is better predicted by the most advanced stage and lymph node status than by the number of primaries.
    • Immunotherapy with BCG is unlikely to prevent the development of new primary melanomas.
    • Further research is needed to understand the factors influencing multiple primary melanoma development and prognosis.